Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

about

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Item

http://www.wikidata.org/entity/Q47915753

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Selecting patients for gastrec ...... and pathology are not enough.

@en

Selecting patients for gastrec ...... and pathology are not enough.

@nl

type

Item

label

Selecting patients for gastrec ...... and pathology are not enough.

@en

Selecting patients for gastrec ...... and pathology are not enough.

@nl

prefLabel

Selecting patients for gastrec ...... and pathology are not enough.

@en

Selecting patients for gastrec ...... and pathology are not enough.

@nl

P1476

Selecting patients for gastrec ...... s and pathology are not enough

@en

P2093

Antonio Pellegrino

http://www.w3.org/2001/XMLSchema#string

Caterina Fontanella

http://www.w3.org/2001/XMLSchema#string

Daniele Santini

http://www.w3.org/2001/XMLSchema#string

Enrico Vasile

http://www.w3.org/2001/XMLSchema#string

Gerardo Rosati

http://www.w3.org/2001/XMLSchema#string

Gianluca Tomasello

http://www.w3.org/2001/XMLSchema#string

Gianna Musettini

http://www.w3.org/2001/XMLSchema#string

Giuseppe Aprile

http://www.w3.org/2001/XMLSchema#string

Lorenzo Antonuzzo

http://www.w3.org/2001/XMLSchema#string

Lorenzo Fornaro

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Comprehensive molecular characterization of gastric adenocarcinoma

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Molecular classification of gastric cancer: a new paradigm.

Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

The role of surgery in metastatic breast cancer.

P304

2265-2275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0246

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28976226

http://www.w3.org/2001/XMLSchema#string

P921

gastrectomy